Navigation Links
Study in Cell by Magen BioSciences Co-Founder David E. Fisher,Identifies New Roles in Skin Cancer Prevention for Key Tumor,Suppressor Protein

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 8, 2007 - Magen BioSciences, Inc., a specialty dermatology company, today announced the publication of a paper in the March 9, 2007 issue of the journal Cell by its co-founder and board member, David E. Fisher, M.D., Ph.D., that identifies two new functions for an important protein, p53, in the pigmentation of skin. Fisher's study shows that in addition to its function as a tumor suppressor in other cancers in the body, p53 also plays a key role in prompting the skin to tan in response to ultraviolet light from the sun. By promoting tanning, p53 deters the development of the skin cancer melanoma, which is increasing in incidence faster than any other cancer in the world.

Fisher's research also shows that p53 causes the production of an endorphin after ultraviolet exposure, and this may modulate sensation in the skin in a manner that influences behaviors, possibly including sun-seeking behaviors.

For Magen BioSciences, the study in Cell provides important proof of concept for the company's approach to identify and develop therapeutic treatments for pigmentation disorders.

"We know that people who tan easily or have dark pigmentation are far less likely to develop melanoma," said David Fisher, with the Dana-Faber Cancer Institute. "This study suggests that p53, one of the best-known tumor-suppressor proteins in our body, goes into action when skin cells experience UV exposure, prompting the skin to tan as a defensive mechanism against DNA damage and at the same time creating endorphins that may alter sensation or even behavior."

"Dr. Fisher's discovery of this new function for a well-known protein sheds new light on the mechanism and function of tanning," said Brian Gallagher, Ph.D., Magen's president and chief executive officer. "This discovery will help Magen BioSciences identify lead compounds and develop therapeutic treatments for disfiguring dermato logical pigmentation disorders such as vitiligo, melasma, solar lentigos and post-inflammation hyperpigmentation."

About Magen BioSciences

Magen BioSciences is a specialty pharmaceutical company focused on developing proprietary medical therapies for the dermatology market. Magen was co-founded in March 2006 by Richard Aldrich, David Fisher, M.D. Ph.D., Phillip Sharp, Ph.D., David Shaw, Christopher Walsh, Ph.D. and Christoph Westphal, M.D., Ph.D. Investors include Alexandria Real Estate, ARCH Venture Partners, Highland Capital Partners, IDG Ventures, Lux Capital, QVT Financial LP, TVM Capital and Venrock Associates.

Contact

for Magen BioSciences, Inc.
Kathryn Morris, 845-635-9828
Kathryn@kmorrispr.com
www.magenbiosciences.com


'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Fla. , Jan. 19, 2017  Sensus ... medical device company specializing in the treatment of ... as keloids, with superficial radiation therapy, today announced ... full year 2016 financial results on Thursday, February 2, ... Company will hold a conference call with the ...
(Date:1/19/2017)... , January 19, 2017 ... announced that the U.S. Food and Drug Administration (FDA) ... a New Drug Application (NDA) for SHP465, a long-acting, ... as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). ... or around June 20, 2017, the designated Prescription Drug ...
(Date:1/19/2017)... January 19, 2017 Pfizer ... the Milner Therapeutics Consortium   Major ... Cambridge   The Milner ... PFE ) as a partner to the Milner Therapeutics ... enables the efficient transfer of materials between industry and ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... ... “I Forgive You”: a fine examination of how God handles sin, including how to ... author, Stephen Miller, who, for over ten long years has been waiting to release this ... and Tobago, he has been serving the Lord for over twenty years, and he has ...
(Date:1/20/2017)... ... ... “The Land of More and More”: a brilliant story for children ... the simple and achievable answer. “The Land of More and More” is the creation ... in Angola, Indiana where he works with the children’s ministry department. , Michael ...
(Date:1/19/2017)... ... 2017 , ... Wells Pharmacy Network announced the completion of ... pharmacy located in Ocala, Florida. , Meeting the Needs of a Growing ... States for high-quality human anti-aging and wellness compounded medications, Wells Pharmacy ...
(Date:1/19/2017)... ... January 19, 2017 , ... Remote Medical Technologies ... impressive transportable capabilities with their iMedHD2™ Portable Teleultrasound System. Compatible ... technology that delivers HD, dynamic, streaming ultrasound images and video to one or ...
(Date:1/19/2017)... ... January 19, 2017 , ... MB Business Capital, ... $11,250,000 senior credit facility to Sunrise, Florida-based Management Health Systems, LLC, dba MedPro ... facilitate a recapitalization of MedPro led by Harren Equity Partners. Brightwood Capital ...
Breaking Medicine News(10 mins):